Arrowhead Pharma

Trials

First posted Jun 12, 2006

Completed

NCT02816970

Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)

24 participants · First posted Jun 29, 2016

Terminated

NCT01058369

Exjade-Early-Trial

2 participants · First posted Jan 28, 2010

Drugs

View all 1114 →

Biotech

Investigational

ARO-ANG3

Manufacturer: Arrowhead Pharmaceuticals, Inc.

Conditions: Homozygous Familial Hypercholesterolemia (HoFH), Mixed Hyperlipidemia

Thalidomide inhalation (Vicore Pharma)

Ezetimibe/obicetrapib (NewAmsterdam Pharma)

Organizations

View all 1222 →

Arrowhead Pharmaceuticals

United States

ARROWHEAD PHARMACEUTICALS INC

United States

Arrowhead Regional Medical Center

United States

News

View all 3256 →

last year

Arrowhead Pharma Focuses on Familial Chylomicronemia Syndrome with Awareness Campaign and Plozasiran Development

last year

Arrowhead Pharmaceuticals' FDA Acceptance of Plozasiran NDA Marks Milestone in RNAi Therapeutics

14 days ago

Trials

Pharma-Pen (Formerly Innoject) Auto-injectory TIV

Bioequivalence Study of Vildagliptin From Gliptus 50 mg Tablet (EVA Pharma, Egypt) and Galvus 50 mg Tablet (NOVARTIS PHARMA, GERMANY)

Exjade-Early-Trial

Drugs

ARO-ANG3

Thalidomide inhalation (Vicore Pharma)

Ezetimibe/obicetrapib (NewAmsterdam Pharma)

Organizations

Arrowhead Pharmaceuticals

ARROWHEAD PHARMACEUTICALS INC

Arrowhead Regional Medical Center

News

Arrowhead Pharma Focuses on Familial Chylomicronemia Syndrome with Awareness Campaign and Plozasiran Development

Arrowhead Pharmaceuticals' FDA Acceptance of Plozasiran NDA Marks Milestone in RNAi Therapeutics

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million